Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Dna X (SONM) Long-Term Debt Issuances (2018 - 2025)

Dna X filings provide 2 years of Long-Term Debt Issuances readings, the most recent being $1.3 million for Q4 2025.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a N/A change, with the full-year FY2025 number at $6.4 million, changed N/A from a year prior.
Long-Term Debt Issuances hit $1.3 million in Q4 2025 for Dna X, down from $2.3 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $2.8 million in Q1 2025 to a low of $1.3 million in Q4 2025.